A carregar...
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation
BACKGROUND: The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, ivacaftor, was first approved for people with CF and the G551D CFTR mutation. This study describes the long-term clinical effectiveness of ivacaftor in this population. METHODS: We conducted a multicenter, prospe...
Na minha lista:
| Publicado no: | J Cyst Fibros |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8183611/ https://ncbi.nlm.nih.gov/pubmed/33249004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2020.11.008 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|